Bolt Biotherapeutics (BOLT) Competitors $5.53 -0.24 (-4.16%) Closing price 03:55 PM EasternExtended Trading$5.53 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. CRIS, SABS, AMGN, GILD, VRTX, ALNY, REGN, BIIB, UTHR, and INCYShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Alnylam Pharmaceuticals (ALNY), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors Curis SAB Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Alnylam Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Incyte Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has better earnings & valuation, BOLT or CRIS? Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.69M1.38-$63.12M-$26.66-0.21Curis$10.91M1.88-$43.39M-$4.88-0.34 Which has more risk & volatility, BOLT or CRIS? Bolt Biotherapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.81, suggesting that its share price is 281% more volatile than the S&P 500. Is BOLT or CRIS more profitable? Bolt Biotherapeutics has a net margin of 0.00% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -91.67% -53.19% Curis -341.24%N/A -102.22% Do analysts prefer BOLT or CRIS? Bolt Biotherapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 758.95%. Curis has a consensus target price of $17.00, suggesting a potential upside of 936.59%. Given Curis' stronger consensus rating and higher probable upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to BOLT or CRIS? In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 1 articles in the media. Curis' average media sentiment score of 1.91 beat Bolt Biotherapeutics' score of 1.89 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Bolt Biotherapeutics Very Positive Curis Very Positive Do institutionals and insiders have more ownership in BOLT or CRIS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 5.5% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCuris beats Bolt Biotherapeutics on 9 of the 14 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.07M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.2120.6375.7726.11Price / Sales1.38442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book0.199.6212.876.30Net Income-$63.12M-$52.73M$3.29B$271.03M7 Day Performance4.54%0.64%-0.26%-0.15%1 Month Performance6.65%6.31%3.84%6.41%1 Year Performance-52.85%18.97%68.35%28.81% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.4708 of 5 stars$5.53-4.2%$47.50+759.0%-51.7%$11.07M$7.69M-0.2190Positive NewsCRISCuris2.7549 of 5 stars$1.70-6.6%$17.00+900.0%-68.5%$22.75M$10.91M-0.3560Positive NewsSABSSAB Biotherapeutics3.8007 of 5 stars$2.10-0.9%$10.67+407.9%-23.7%$22.07M$1.32M-0.53140AMGNAmgen4.775 of 5 stars$274.40-0.7%$304.43+10.9%-15.6%$148.80B$33.42B22.4428,000Positive NewsAnalyst ForecastGILDGilead Sciences4.9627 of 5 stars$112.54-1.8%$115.39+2.5%+35.7%$142.13B$28.86B22.4217,600Trending NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.9102 of 5 stars$393.21-0.3%$496.05+26.2%-18.7%$101.15B$11.02B28.116,100Trending NewsAnalyst UpgradeAnalyst RevisionALNYAlnylam Pharmaceuticals3.6134 of 5 stars$461.14-1.0%$421.28-8.6%+69.1%$61.07B$2.25B-186.702,230REGNRegeneron Pharmaceuticals4.7443 of 5 stars$572.59+2.2%$817.67+42.8%-44.8%$59.35B$14.20B14.4315,106Positive NewsBIIBBiogen4.6457 of 5 stars$143.32-1.1%$181.65+26.7%-29.1%$21.24B$9.68B13.707,605Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.515 of 5 stars$403.11-0.5%$438.85+8.9%+22.6%$18.27B$2.88B15.731,305Insider TradeINCYIncyte4.7567 of 5 stars$83.14+0.0%$82.53-0.7%+32.1%$16.23B$4.58B18.902,617Analyst Forecast Related Companies and Tools Related Companies Curis Alternatives SAB Biotherapeutics Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLT Stock Alerts